|Title:||Paramagnetic DTPA and EDTA alkoxyalkylamide complexes as MRI agents|
|Abstract:||Novel magnetic resonance imaging agents and methods which utilize complexes of paramagnetic ions with alkoxyalkylamide derivatives of diethylenetriaminepentaacetic acid ("DTPA") or ethylenediaminetetraacetic acid ("EDTA"). These novel imaging agents are characterized by excellent NMR image-contrasting properties and by high solubilities in physiological solutions. The complexes are represented by the following formula: ##STR1## wherein A is --CH.sub.2 CH.sub.2 -- or ##STR2## and M.sup.+z is a paramagnetic ion of an element with an atomic number of 21-29, 42-44 or 58-70, and a valence, Z, of 2 or 3; the R groups may be the same or different and are selected from the group consisting of -O.sup..crclbar. and lower alkoxyalkylamino groups having from 2 to about 6 carbon atoms, wherein the number of R groups -O.sup..crclbar. equals Z and the remaining R groups are lower alkoxyalkylamino, equal to 4-Z when A is --CH.sub.2 CH.sub.2 --, or 5-Z when A ##STR3##|
|Inventor(s):||Weber; Robert W. (Downingtown, PA)|
|Assignee:||Mallinckrodt Medical, Inc. (St. Louis, MO)|
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Dosage form; Use;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.